Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — December 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • D Offline
    D Offline
    Doublo
    wrote on sidst redigeret af
    #868

    De snuppede 5,5 kurspoint på Vestas

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #869

      Helt klart. 2 stks på vinderlisten og stort plus i pf er meget fint.

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #870

        Men derfor kan det alligevel undre at genmab skulle køre så dårligt i dag. Tepezza eller ej.

        1 Reply Last reply
        0
        • D Offline
          D Offline
          Doublo
          wrote on sidst redigeret af
          #871

          Bulder for 2 dage siden håbede vi bare den holdt sig over 2400, den stiger på mandag! 🙂

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #872

            Gu' gør den da det. Skulle da bare mangle. Prøver bare at finde en forklaring på i dag. Og kan kun komme på Tepezza.

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #873

              🙂

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #874

                Jeg regner med at på mandag falder C25 som en sten, mens Gen tager revanche.

                1 Reply Last reply
                0
                • K Offline
                  K Offline
                  Klarussen
                  wrote on sidst redigeret af
                  #875

                  Nogen der kan læse det her? Lyder
                  spændende: https://ugebrev.dk/life-science/selskabsanalyser/genmab-mod-nye-hoejder-i-det-nye-aar/?mc_cid=115bcdb3b5&mc_eid=5805bdd5ee

                  1 Reply Last reply
                  0
                  • K Offline
                    K Offline
                    Klarussen
                    wrote on sidst redigeret af
                    #876

                    GENMAB – mod nye højder i det nye år!
                    Af David Mygind d. 18/12
                    Forventningerne til dette års ASH-konference var skyhøje, men der blev leveret som ventet, og der er nu linet op til et kapløb mellem Genmab og Roche indenfor de bi-specifikke antistoffer i NHL. Efter lidt konsolidering omkring det nuværende kursleje virker aktien nu klar til at bevæge sig op i nye højder i det nye år. …

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #877

                      God morgen. 🙂

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        Klarussen
                        wrote on sidst redigeret af
                        #878

                        En vel i dag
                        endnu mere aktuel artikel fra 2016, sjovt her i slutningen af 2020 at læse den igen: https://www.proinvestor.com/boards/74456

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #879

                          Epcoritamab has entered the EMA paper-mountain... 3.1.40. Epcoritamab - EMEA-002907-PIP01-20
                          Treatment of mature B-cell lymphoma / Treatment of paediatric patients with
                          relapsed/refractory aggressive mature B-cell lymphoma
                          Day 30 discussion
                          Action: For discussion
                          Oncology https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-8-11-december-2020-meeting_en.pdf

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #880

                            Ofa is in there also for MS

                            1 Reply Last reply
                            0
                            • bongobobB Offline
                              bongobobB Offline
                              bongobob
                              wrote on sidst redigeret af
                              #881

                              Why paediatric? The current Epco studies does not include children

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #882

                                it is probably to get a product-specific waiver by the Paediatric Committee so that they don't have to take care of any specific paediatric regulations ; that seems to be the 'normal' route for many of these drugs

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #883

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #884

                                    Mandagens aviser med Pandora, Mærsk og Danske Bank: https://www.proinvestor.com/investornyt/670532/mandagens-aviser-med-pandora-maersk-og-danske-bank

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #885

                                      Aktier/tendens: Fokus på fredagens
                                      trækheste i ventet rød åbning. https://www.proinvestor.com/investornyt/670538/aktier-tendens-fokus-pa-fredagens-traekheste-i-ventet-rod-abning

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #886

                                        This case emphasizes that, with the availability of novel immunotherapy agents (Daratumumab), and repurposed use of bortezomib, a patient with HIV‐negative relapsed PBL can be treated successfully https://onlinelibrary.wiley.com/doi/10.1002/ccr3.3673

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #887

                                          Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication https://endpts.com/best-selling-tagrisso-further-outpaces-an-upcoming-jj-rival-winning-approval-in-new-nsclc-indication/

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger